<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175757</url>
  </required_header>
  <id_info>
    <org_study_id>CL086</org_study_id>
    <nct_id>NCT03175757</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels</brief_title>
  <official_title>A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels Among Generally Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supplement Formulators, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supplement Formulators, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of a turmeric and black cumin seed
      formulation on cholesterol levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single-blind, placebo-controlled study to evaluate the effects of
      a turmeric and black cumin seed formulation on cholesterol levels. Each subject will receive
      a specific dose of the formulation or placebo twice daily. Participants will undergo
      assessments of blood tests, vital signs, body weight, waist circumference, hip circumference
      and waist-to-hip ratio with completion of a questionnaire.

      The primary objective of the study is to assess the effects of the turmeric and black cumin
      seed formulation on fasting levels of Total Cholesterol.

      Secondary objectives include assessment of the effects of turmeric and black cumin seed
      formulation on: fasting levels of: LDL Cholesterol, parameters in the NMR LipoProfileÂ®,
      Oxidized LDL, Triglycerides, HDL cholesterol, C-reactive protein, blood glucose, Insulin and
      Hemoglobin A1c, as well as the assessments of the values/scores of body weight, waist
      circumference, hip circumference, waist-to-hip ratio, blood pressure and the SF-36 survey
      scores.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Anticipated">June 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (hs-CRP)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Day 1 (Enrollment) to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Day 1 (Enrollment) to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 health survey scores</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Day 1 (Enrollment) to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Day 1 (Enrollment) to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Day 1 (Enrollment) to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Hip ratio</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Day 1 (Enrollment) to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-P (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol, Total (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-P (Total) (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small LDL-P (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Size (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LP-IR Score (NMR Lipoprofile)</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change from Baseline/screening to Day 60</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cholesterol Health</condition>
  <arm_group>
    <arm_group_label>Cholesterol Health Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Turmeric and black cumin seed preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Turmeric and Black Cumin Seed</intervention_name>
    <description>Turmeric and Black Cumin Seed formulation</description>
    <arm_group_label>Cholesterol Health Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ambulatory, male or female, between 40 and 75 years of age

          2. Meeting one of the following two criteria:

               1. Having a BMI between 25.0 and 34.9

               2. Waist circumference &gt; 40.0 inches in males and &gt; 35.0 inches in females

          3. Having Total Cholesterol levels at Baseline/screening of between 190 and 239 mg/dl

          4. Generally healthy and having no difficulty with digestion or absorption of food

          5. Willing and able to give written informed consent

          6. Clearly understands the procedures and requirements for the study

          7. Able to maintain stable physical activity and dietary habits throughout the study

          8. Willing and able to comply with all study procedures and data recording obligations

          9. Having the capability of communicating, including reading in English

        Exclusion Criteria:

          1. Having smoked any cigarette, electronic cigarette, cigar, pipe, or recreational drug
             in the past 30 days

          2. History of allergy or sensitivity to any component of the study products

          3. Donation of blood within 30 days prior Baseline/screening

          4. Participation in another study within 30 days prior to Baseline/screening

          5. Being pregnant, planning on becoming pregnant during study participation or breast
             feeding

          6. Having the following medical condition(s): diabetes, hypotension, hypertension
             (changed antihypertensive medication or dose in the preceding 3 months and/or likely
             to do so during the study), cardiovascular disease (arrhythmia, edema with or without
             congestive heart failure, heart attack, stroke, abnormal EKG), gastrointestinal
             disease requiring daily prescribed medication (gastroesophageal reflux, gastritis, and
             peptic or duodenal ulcer), gallbladder disease or gallstones, biliary obstruction
             (past or present), endocrine disease (hyper- or hypothyroidism), psychiatric disorder
             (anxiety if untreated, eating disorder) neurologic disease (Parkinson's disease,
             intracranial hemorrhage, head injury, brain tumor, evidence of delirium, confusion,
             dementia, Alzheimer's disease, migraine headache (if last migraine headache was &lt; 3
             years prior to Baseline/screening), urologic disease, chronic inflammatory or
             autoimmune disease, cancer (unless skin cancer other than melanoma which has been
             treated &gt; 3 years prior to Baseline/screening), liver and kidney disease, insomnia,
             blood coagulation disorder (anemia, thrombus, embolism), sleep apnea, or other
             condition(s) that would preclude participation in the study in the judgment of the
             investigator/sub-investigator (Sub-I).

          7. Currently taking or having taken cholesterol-lowering medication(s) including HMGCR
             inhibitors, cholesterol binding resins, fibrates, or nicotinic acid &gt;1 gram/day within
             30 days prior to screening

          8. Currently taking or having taken a supplemental product that may affect cholesterol
             levels (red yeast rice, red mold dioscorea, guggulipid, policosanol, pantethine,
             beta-sitosterol, artichoke leaf, or supplemental fiber) within 30 days prior to
             Baseline/screening

          9. Currently taking or having taken a fish oil or krill oil product within 30 days prior
             to Baseline/screening

         10. Currently taking or having taken anxiolytics and sedative hypnotics, anticonvulsants,
             antineoplastics, anti-migraine medication(s), opioid analgesics, monoamine oxidase
             inhibitors (MAOIs), phosphodiesterase inhibitors, adenosine reuptake inhibitors,
             dopamine agonists, dopamine antagonists, or immunosuppressants within 30 days prior to
             Baseline/screening

         11. Currently talking or having taken anti-inflammatory medication(s) within 14 days prior
             to screening (unless on a stable daily dose of aspirin 81mg for 3 months prior to
             screening and not likely to change dose during the study) or in the judgment of the
             PI/Sub-I would not preclude participation in the study

         12. Having had a surgical procedure, pacemaker or any internal medical device other than
             artificial joints which, in the judgment of the PI/Sub-I, would preclude participation
             in the study

         13. Having had a routine dental cleaning or other dental procedure within 14 days prior to
             Baseline/screening

         14. Having screening laboratory test values: bilirubin &gt; 2.5 x ULN, AST/SGOT and ALT/SGPT
             &gt; 2.5 x ULN, serum creatinine &gt; 1.5 mg/dL, blood glucose &gt; 125 mg/dL, or any other lab
             test result(s) that would preclude participation in the study in the judgment of the
             PI/Sub-I

         15. Having blood pressure readings at Baseline/screening &gt; 140 systolic or &gt; 90 diastolic
             on two consecutive readings unless permitted to proceed to the next visit in the
             judgment of the PI/Sub-I

         16. Currently consumes more than 6 standard alcoholic drinks per week (a standard
             alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce
             of hard liquor)

         17. History of known alcohol or substance abuse (e.g., opiates, benzodiazepines, or
             amphetamines)

         18. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville
             oranges and tangelos

         19. Having any other significant circumstance that would preclude study participation in
             the judgment of the PI/Sub-I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Joyal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Life Extension</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Steven Hirsh</last_name>
    <phone>866-517-4536</phone>
    <phone_ext>7679</phone_ext>
    <email>shirsh@lifeextension.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Life Extension Clinical Research, Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Steven Hirsh</last_name>
      <phone>866-517-4536</phone>
      <phone_ext>7679</phone_ext>
      <email>shirsh@lifeextension.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Cunningham</last_name>
      <phone>866-517-4536</phone>
      <phone_ext>7737</phone_ext>
      <email>mcunningham@lifeextension.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahmad S, Beg ZH. Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem. 2013 Jun 1;138(2-3):1116-24. doi: 10.1016/j.foodchem.2012.11.109. Epub 2012 Dec 5.</citation>
    <PMID>23411222</PMID>
  </reference>
  <reference>
    <citation>Al-Naqeep G, Al-Zubairi AS, Ismail M, Amom ZH, Esa NM. Antiatherogenic Potential of Nigella sativa Seeds and Oil in Diet-Induced Hypercholesterolemia in Rabbits. Evid Based Complement Alternat Med. 2011;2011:213628. doi: 10.1093/ecam/neq071. Epub 2011 Jun 16.</citation>
    <PMID>21792359</PMID>
  </reference>
  <reference>
    <citation>Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003 Apr;17(4):299-305. Review.</citation>
    <PMID>12722128</PMID>
  </reference>
  <reference>
    <citation>Amin F, Gilani AH, Mehmood MH, Siddiqui BS, Khatoon N. Coadministration of black seeds and turmeric shows enhanced efficacy in preventing metabolic syndrome in fructose-fed rats. J Cardiovasc Pharmacol. 2015 Feb;65(2):176-83. doi: 10.1097/FJC.0000000000000179.</citation>
    <PMID>25384193</PMID>
  </reference>
  <reference>
    <citation>Amin F, Islam N, Anila N, Gilani AH. Clinical efficacy of the co-administration of Turmeric and Black seeds (Kalongi) in metabolic syndrome - a double blind randomized controlled trial - TAK-MetS trial. Complement Ther Med. 2015 Apr;23(2):165-74. doi: 10.1016/j.ctim.2015.01.008. Epub 2015 Jan 14.</citation>
    <PMID>25847554</PMID>
  </reference>
  <reference>
    <citation>Asgary S, Sahebkar A, Goli-Malekabadi N. Ameliorative effects of Nigella sativa on dyslipidemia. J Endocrinol Invest. 2015 Oct;38(10):1039-46. doi: 10.1007/s40618-015-0337-0. Epub 2015 Jul 2. Review.</citation>
    <PMID>26134064</PMID>
  </reference>
  <reference>
    <citation>Bamosa AO, Ali BA, al-Hawsawi ZA. The effect of thymoquinone on blood lipids in rats. Indian J Physiol Pharmacol. 2002 Apr;46(2):195-201.</citation>
    <PMID>12500494</PMID>
  </reference>
  <reference>
    <citation>Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011 Mar;4(3):354-64. doi: 10.1158/1940-6207.CAPR-10-0098. Erratum in: Cancer Prev Res (Phila). 2012 Dec;5(12):1407. Dosage error in article text.</citation>
    <PMID>21372035</PMID>
  </reference>
  <reference>
    <citation>Chen FY, Zhou J, Guo N, Ma WG, Huang X, Wang H, Yuan ZY. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun. 2015 Nov 27;467(4):872-8. doi: 10.1016/j.bbrc.2015.10.051. Epub 2015 Oct 19.</citation>
    <PMID>26471308</PMID>
  </reference>
  <reference>
    <citation>Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.</citation>
    <PMID>11712783</PMID>
  </reference>
  <reference>
    <citation>Dahri AH, Chandiol AM, Rahoo AA, Memon RA. Effect of Nigella sativa (kalonji) on serum cholesterol of albino rats. J Ayub Med Coll Abbottabad. 2005 Apr-Jun;17(2):72-4.</citation>
    <PMID>16092657</PMID>
  </reference>
  <reference>
    <citation>Dollah MA, Parhizkar S, Latiff LA, Bin Hassan MH. Toxicity effect of nigella sativa on the liver function of rats. Adv Pharm Bull. 2013;3(1):97-102. doi: 10.5681/apb.2013.016. Epub 2013 Feb 7.</citation>
    <PMID>24312819</PMID>
  </reference>
  <reference>
    <citation>Dong SZ, Zhao SP, Wu ZH, Yang J, Xie XZ, Yu BL, Nie S. Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma-LXRalpha-ABCA1 passway. Mol Cell Biochem. 2011 Dec;358(1-2):281-5. doi: 10.1007/s11010-011-0978-z. Epub 2011 Jul 12.</citation>
    <PMID>21748336</PMID>
  </reference>
  <reference>
    <citation>Fan C, Wo X, Dou X, Xu L, Qian Y, Luo Y, Yan J. Regulation of LDL receptor expression by the effect of curcumin on sterol regulatory element pathway. Pharmacol Rep. 2006 Jul-Aug;58(4):577-81.</citation>
    <PMID>16963807</PMID>
  </reference>
  <reference>
    <citation>Haas MJ, Onstead-Haas LM, Naem E, Wong NC, Mooradian AD. Induction of apolipoprotein A-I gene expression by black seed (Nigella sativa) extracts. Pharm Biol. 2014 Sep;52(9):1119-27. doi: 10.3109/13880209.2013.879187. Epub 2014 Mar 17.</citation>
    <PMID>24635344</PMID>
  </reference>
  <reference>
    <citation>Heshmati J, Namazi N. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review. Complement Ther Med. 2015 Apr;23(2):275-82. doi: 10.1016/j.ctim.2015.01.013. Epub 2015 Feb 9. Review.</citation>
    <PMID>25847566</PMID>
  </reference>
  <reference>
    <citation>Hosseinzadeh H, Parvardeh S, Asl MN, Sadeghnia HR, Ziaee T. Effect of thymoquinone and Nigella sativa seeds oil on lipid peroxidation level during global cerebral ischemia-reperfusion injury in rat hippocampus. Phytomedicine. 2007 Sep;14(9):621-7. Epub 2007 Feb 8.</citation>
    <PMID>17291733</PMID>
  </reference>
  <reference>
    <citation>Ibrahim RM, Hamdan NS, Ismail M, Saini SM, Abd Rashid SN, Abd Latiff L, Mahmud R. Protective Effects of Nigella sativa on Metabolic Syndrome in Menopausal Women. Adv Pharm Bull. 2014;4(1):29-33. doi: 10.5681/apb.2014.005. Epub 2013 Dec 23.</citation>
    <PMID>24409406</PMID>
  </reference>
  <reference>
    <citation>Kaatabi H, Bamosa AO, Lebda FM, Al Elq AH, Al-Sultan AI. Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients. J Family Community Med. 2012 Sep;19(3):155-61. doi: 10.4103/2230-8229.102311.</citation>
    <PMID>23230380</PMID>
  </reference>
  <reference>
    <citation>Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014 Mar 20;9:451-8. doi: 10.2147/CIA.S58535. eCollection 2014.</citation>
    <PMID>24672232</PMID>
  </reference>
  <reference>
    <citation>Lin XL, Liu MH, Hu HJ, Feng HR, Fan XJ, Zou WW, Pan YQ, Hu XM, Wang Z. Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRÎ± signaling in THP-1 macrophage-derived foam cells. DNA Cell Biol. 2015 Sep;34(9):561-72. doi: 10.1089/dna.2015.2866. Epub 2015 Jun 23.</citation>
    <PMID>26102194</PMID>
  </reference>
  <reference>
    <citation>Liu T, Li C, Sun H, Luo T, Tan Y, Tian D, Guo Z. Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage. Inflamm Res. 2014 Oct;63(10):841-50. doi: 10.1007/s00011-014-0758-9. Epub 2014 Jul 27.</citation>
    <PMID>25064633</PMID>
  </reference>
  <reference>
    <citation>Mirzabeigi P, Mohammadpour AH, Salarifar M, Gholami K, Mojtahedzadeh M, Javadi MR. The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial. Iran J Pharm Res. 2015 Spring;14(2):479-86.</citation>
    <PMID>25901155</PMID>
  </reference>
  <reference>
    <citation>Mooradian AD, Haas MJ. The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiovasc Drugs. 2014 Aug;14(4):253-74. doi: 10.1007/s40256-014-0068-1. Review.</citation>
    <PMID>24604774</PMID>
  </reference>
  <reference>
    <citation>Morrone Mda S, Schnorr CE, Behr GA, Gasparotto J, Bortolin RC, da Boit Martinello K, Saldanha Henkin B, Rabello TK, Zanotto-Filho A, Gelain DP, Moreira JC. Curcumin Supplementation Decreases Intestinal Adiposity Accumulation, Serum Cholesterol Alterations, and Oxidative Stress in Ovariectomized Rats. Oxid Med Cell Longev. 2016;2016:5719291. doi: 10.1155/2016/5719291. Epub 2015 Nov 23.</citation>
    <PMID>26640615</PMID>
  </reference>
  <reference>
    <citation>Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, Sahebkar A. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition. 2016 Oct;32(10):1116-22. doi: 10.1016/j.nut.2016.03.018. Epub 2016 Mar 31.</citation>
    <PMID>27297718</PMID>
  </reference>
  <reference>
    <citation>Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-MendÃ­a LE, Sahebkar A. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J Cardiovasc Pharmacol. 2016 Sep;68(3):223-9. doi: 10.1097/FJC.0000000000000406.</citation>
    <PMID>27124606</PMID>
  </reference>
  <reference>
    <citation>Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem. 2007 Feb;18(2):113-9. Epub 2006 May 18.</citation>
    <PMID>16713233</PMID>
  </reference>
  <reference>
    <citation>Ragheb A, Elbarbry F, Prasad K, Mohamed A, Ahmed MS, Shoker A. Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int J Angiol. 2008 Winter;17(4):186-92.</citation>
    <PMID>22477447</PMID>
  </reference>
  <reference>
    <citation>Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014 Apr;28(4):579-85. doi: 10.1002/ptr.5025. Epub 2013 Jul 6.</citation>
    <PMID>23832433</PMID>
  </reference>
  <reference>
    <citation>Sahebkar A, Beccuti G, Simental-MendÃ­a LE, Nobili V, Bo S. Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016 Apr;106:37-50. doi: 10.1016/j.phrs.2016.02.008. Epub 2016 Feb 10. Review.</citation>
    <PMID>26875640</PMID>
  </reference>
  <reference>
    <citation>Shafiq H, Ahmad A, Masud T, Kaleem M. Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci. 2014 Dec;17(12):967-79. Review.</citation>
    <PMID>25859300</PMID>
  </reference>
  <reference>
    <citation>Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001 Jul;7(7):1894-900.</citation>
    <PMID>11448902</PMID>
  </reference>
  <reference>
    <citation>Shuid AN, Mohamed N, Mohamed IN, Othman F, Suhaimi F, Mohd Ramli ES, Muhammad N, Soelaiman IN. Nigella sativa: A Potential Antiosteoporotic Agent. Evid Based Complement Alternat Med. 2012;2012:696230. doi: 10.1155/2012/696230. Epub 2012 Sep 3.</citation>
    <PMID>22973403</PMID>
  </reference>
  <reference>
    <citation>Singh V, Jain M, Misra A, Khanna V, Rana M, Prakash P, Malasoni R, Dwivedi AK, Dikshit M, Barthwal MK. Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters. Br J Nutr. 2013 Aug 28;110(3):437-46. doi: 10.1017/S0007114512005363. Epub 2013 May 15.</citation>
    <PMID>23673139</PMID>
  </reference>
  <reference>
    <citation>Singh V, Rana M, Jain M, Singh N, Naqvi A, Malasoni R, Dwivedi AK, Dikshit M, Barthwal MK. Curcuma oil attenuates accelerated atherosclerosis and macrophage foam-cell formation by modulating genes involved in plaque stability, lipid homeostasis and inflammation. Br J Nutr. 2015 Jan 14;113(1):100-13. doi: 10.1017/S0007114514003195. Epub 2014 Nov 13.</citation>
    <PMID>25391643</PMID>
  </reference>
  <reference>
    <citation>Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res. 2014 Nov;58(11):2133-45. doi: 10.1002/mnfr.201400366. Epub 2014 Sep 19.</citation>
    <PMID>25164566</PMID>
  </reference>
  <reference>
    <citation>Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014 Dec;28(12):1770-7. doi: 10.1002/ptr.5197. Epub 2014 Aug 6.</citation>
    <PMID>25131839</PMID>
  </reference>
  <reference>
    <citation>Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol. 2002 Jan;79(1):23-6.</citation>
    <PMID>11744291</PMID>
  </reference>
  <reference>
    <citation>Zhao JF, Ching LC, Huang YC, Chen CY, Chiang AN, Kou YR, Shyue SK, Lee TS. Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res. 2012 May;56(5):691-701. doi: 10.1002/mnfr.201100735.</citation>
    <PMID>22648616</PMID>
  </reference>
  <reference>
    <citation>Zingg JM, Hasan ST, Meydani M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors. 2013 Jan-Feb;39(1):101-21. doi: 10.1002/biof.1072. Epub 2013 Jan 22. Review.</citation>
    <PMID>23339042</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Turmeric extract</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

